Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A clinical overview of infection in patients receiving elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) for newly diagnosed multiple myeloma in the MagnetisMM-6 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

LPLuděk PourJMJiří MinaříkEAElham Askari

Discussion

Loading...

Member takes

Overview

Randomized trial identifies high infection rates in patients with NDMM receiving EDR, suggesting a need for prophylaxis and close monitoring.

Key Points

  • This research aims to assess infection profiles and safety in NDMM patients receiving EDR treatment.
  • Open-label, 2-arm, randomized, phase 3 trial
  • Patients received combinations of ELRA, DARA, and R
  • Infections were monitored during treatment
  • Safety and efficacy profiles were evaluated over several cycles
  • 70.3% of patients experienced infections, mostly within 8 weeks of treatment initiation
  • Common infections included pneumonia and urinary tract infections
  • Neutropenia was reported in 73.0% of patients, indicating immunosuppression risks

Cite This Study

Pour et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d068https://doi.org/10.1182/blood-2025-2253
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of tumor burden on the risk of cytokine release syndrome (CRS) in patients with multiple myeloma treated with elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) in the MagnetisMM-6 trial2025 · 1 citations
  2. 2Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial2025 · 8 citations
  3. 3Safety and efficacy of elranatamab + nirogacestat in patients with relapsed or refractory multiple myeloma: Results from the Phase 1b MagnetisMM-4 study2025
  4. 4Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-32025 · 3 citations
  5. 5Comparison of elranatamab's progression-free survival, duration of response, and overall survival from MagnetisMM-3 versus real-world external control arms: A subgroup analysis of China-predominant treatment regimens2025